Health Equity & Where it Goes Wrong, Extending Time to Next Treatment for CLL

In this episode, we have two interviews: one general, but incredibly entertaining, about health equity and one on a clinical study in chronic lymphocytic leukemia (CLL). This last interview is with Ryan Jacobs, MD (Dept. Hematology, Atrium Health Levine Cancer Institute), who discusses his new real-world study using more than 2 years of EMRs that shows that patients with CLL treated with first-line Bruton’s tyrosine kinase inhibitor (BTKi) acalabrutinib were 89% more likely to initiate a next-line treatment when compared with patients treated with another BTKi first-line ibrutinib. But first, Physician’s Weekly Editorial Board member and frequent contributor Alex McDonald, MD, speaks with La Tanya Hines, MD, a board-certified obstetrician and gynecologist practicing in Los Angeles about health equity—what it is and where it goes wrong.

Enjoy listening!

Additional reading:

https://www.diversityinmedicine.uci.edu/dr-la-tanya-hines/

Jacobs R. et al, Real-World Comparison of Time to Next Treatment for Patients with CLL Initiated on First-Line Treatment with Ibrutinib Versus Acalabrutinib. Presented at the American Society of Hematology (ASH 2022) on Monday, December 12, 2022, Abstract 797.

Lu X, et al. Real-World Adherence to First-Line Ibrutinib and Acalabrutinib Single-Agent Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Lymphoma Myeloma and Leukemia, Volume 22, Supplement 2, 2022: S280-S281, abstract CLL-492

Let us know what you thought of this week’s episode on Twitter: @physicianswkly

Want to share your medical expertise, research, or unique experience in medicine on the PW podcast? Email us at editorial@physweekly.com!

Thanks for listening!